What's Happening?
Leo Cancer Care has successfully raised $40 million in a funding round led by Catalio Capital Management to commercialize its upright radiotherapy system, Marie®. This system, designed for proton therapy, offers a patient-friendly approach by replacing gantry rotation with patient rotation, reducing the size, cost, and complexity of treatment. The Marie® system has received FDA clearance and is being installed at leading cancer centers in the U.S., with patient treatments expected to begin later in 2025. The funding will accelerate the system's commercialization and expand access to advanced cancer treatments.
Why It's Important?
The investment in Leo Cancer Care's upright radiotherapy system represents a significant advancement in cancer treatment technology. By making proton therapy more accessible and cost-effective, the Marie® system has the potential to improve patient experiences and expand treatment options globally. This development is crucial for healthcare providers and patients seeking innovative solutions to cancer care. The funding also underscores the growing recognition of upright radiotherapy's potential to transform the industry.
What's Next?
With the new funding, Leo Cancer Care will focus on the commercialization of the Marie® system, aiming to install it in more cancer centers and begin patient treatments. The company will continue to work on expanding its market presence and enhancing the accessibility of advanced radiotherapy treatments. Stakeholders in the healthcare industry will be watching closely as the system is integrated into clinical practice.
